The objective was to investigate the relationship of disease severity, health beliefs and medication adherence among HIV/AIDS patients. A survey was administered to 72 patients in three different stages of HIV/AIDS (CDC clinical categories A, B, C). Multivariate analyses revealed that there were no signi cant differences in patients' perceptions of the severity of HIV/AIDS or perceptions of the bene ts and barriers for the treatment across three disease stages. However, the most severely ill patients (in stage C) perceived a higher risk of complications if they did not take their medicine as prescribed compared to asymptomatic patients (stage A) (p 5 0.01). Also, patients in stages B and C were more adherent to their medications compared to patients in stage A (p 5 0.007). Finally, perceived susceptibility-inaction was positively related to medication adherence (p 5 0.005) and dif culty in following doctors' instructions was negatively related to patients' medication adherence (p 5 0.009). In conclusion, patients' illness experiences are associated with their beliefs about the chances of developing complications if they do not adhere to their medications. Patients who have experienced more complications perceive a stronger relationship between medication non-adherence and AIDS-related complications, and are also more adherent to their medication regimen when compared to patients with no prior complications.
Introduction
HIV/AIDS is often viewed as a chronic, fatal illness that is managed with multiple drug therapies. Patient medication adherence is essential to the success of drug therapy. It is particularly important with antiretroviral agents. Continuous treatment is required for sustained viral suppression (Havlir & Richman, 1996) .
Patients' beliefs about disease and medications are crucial to their intentional adherence behaviours and may be very different than those of providers (Donovan & Blake, 1992) . The most widely used rational belief theory for explaining health behaviours is the Health Belief Model (HBM), which was rst introduced by Rosenstock (1966) . It has been frequently used as the major theoretical or organizing framework for explaining and predicting adherence to health and medical care recommendations (Geletko et al., 1995; Janz & Becker, 1984; Morse et al., 1991; Muma et al., 1995) .
In recent years, some researchers have advocated change in the structure and measurement of the HBM. Ronis (1992) suggested that the concept of bene ts includes all anticipated desirable consequences of an action and the concept of costs includes all anticipated undesirable consequences of an action. Ronis also suggests that the concepts of susceptibility and severity need to be made conditional on alternative actions or inaction. For example, it is important to distinguish between: (1) perceived susceptibility to a disease/disease progression when preventive action is taken; and (2) perceived susceptibility to a disease/disease progression when no preventive action is taken. Therefore, perceived susceptibility and severity should be evaluated in a given condition in which the action (e.g. adhering to the treatment) will or will not be taken. High susceptibility given inaction is associated with higher possibility of taking the action and high susceptibility given action is associated with lower possibility of taking the action. Similarly, high perceived severity given inaction is associated with higher possibility of taking the action and high severity given action is associated with lower possibility of taking the action (Ronis, 1992) .
The revised HBM was well supported by the studies of breast cancer screening behaviour (Ronis & Harel, 1989) , breast self-examination behaviour (Ronis & Kaiser, 1989 ) and dental ossing behaviour (Ronis, 1992) . Using this model to assess HIV patients' beliefs regarding HIV/AIDS and its treatment should provide insight on their adherence to the treatments.
Studies have also shown that medication-taking behaviours may be related to the severity of disease (Graham et al., 1994; Smith 1999; Spilker, 1992) . Among HIV patients, symptoms can vary greatly in frequency and severity. In the early stages of the disease, for example, there may be no symptoms experienced by the patient (Grif th, 1990) . Hence, some patients in this stage may be more sensitive to the side effects of the medication despite its bene ts and may not experience any decline in health soon after discontinuing their medications. Patients with more advanced HIV disease have experienced more symptoms and may have noticed a more profound relationship between adherence to their drug regimen and their wellbeing.
While several studies have examined the determinants of non-adherence in patients with HIV/AIDS (Geletko et al., 1995; Morse et al., 1991; Muma et al., 1995) , only a few studies have directly examined how the severity of HIV/AIDS may affect patients' adherence to medications. A study conducted by Samet et al. (1992) included patients with non-symptoms, mild symptoms and patients with AIDS or ARC. They did nd adherence behaviours were associated with the diagnosis of AIDS or ARC and the patient belief that zidovudine prolonged life. However, there was no examination of the relationship between the diagnosis (stage of HIV infection) and the beliefs of the patient. A study by Smith et al. (1999) found a signi cant association between CD4 1 cell count, having a usual source of health care, ambulatory visits and use of antiretrovirals at each of the three stages of HIV disease. However, Smith's study did not use the categories de ned by Centers for Disease Control and Prevention (CDC) to differentiate the patients' experience with the clinical complications of HIV, nor did they examine how health beliefs change over the course of HIV/AIDS. Disease severity has been shown to in uence health beliefs about the disease and treatment (Conner & Norman, 1994; Geletko et al., 1995; Rosenstock, 1966) . Patients' beliefs and attitudes may vary with their disease status and experiences. Two possible explanations for the effects of disease severity on adherence behaviours are: (1) changes in patients' health beliefs based upon their experience with the disease and its treatment; and (2) an increased treatment regimen complexity associated with increasing disease severity.
Consequently, one might suspect that the relationship between the severity of a disease and medication adherence is mediated by one's health beliefs, or simply mediated by an increased treatment regimen complexity, or both. However, no study has veri ed this proposed relationship between disease severity, health beliefs and treatment adherence. Very little is known about how disease severity affects perceptions of health status, perceived bene ts and perceived barriers of treatment, and further affects decision-making regarding medication adherence among HIV/AIDS patients.
This study investigated the relationship of disease severity, health beliefs and medication-taking behaviours among HIV patients. The objectives are to: (1) compare health beliefs regarding HIV/AIDS and its treatment among HIV patients in different disease stages;
(2) examine medication adherence of HIV patients with antiretroviral therapy in different disease stages; and (3) investigate the in uence of regimen complexity and health beliefs on self-reported medication adherence.
Methods

Sample selection and data collection
The sample was drawn from an infectious disease clinic at West Virginia University Hospital (WVUH), and the AIDS clinics at Charleston Area Medical Center (CAMC) and University of Maryland Hospital (UMH). Patients were eligible for this study if they met the following criteria: (1) con rmed diagnosis of HIV infection; (2) using antiretroviral therapy for at least one month; (3) age 18 years or older, and (4) mentally competent.
Data were collected over a six-month period from May to December 1998 by using a convenience sample of patients visiting the AIDS clinics. Patients who met the inclusion criteria were informed by the physician, or the clinic pharmacist, about the purpose and nature of the study. Written information regarding the study and the patient's right to refusal were provided. Patients who agreed to participate were given the written questionnaire on which their clinic pharmacist or physician had indicated the patient's disease stage. The patients were classi ed as stage A, B or C according to the CDC criteria (CDC, 1992) . The disease category was selected based upon whether the patient had ever experienced the indicator conditions, rather than his or her current status. The patients were allowed to complete the survey in the clinic or take it home. They were instructed to seal the questionnaire within a stamped return envelope and to either return the sealed envelope to the clinic pharmacist or to place it in the mail. All questionnaires were sent directly to the researchers at WVU to ensure the anonymity of responses.
Measurement
Based on a literature review and expert panel (the clinical pharmacists and physicians in both WVUH and CAMC), items were developed to measure health beliefs, regimen complexity and medication-taking behaviours of HIV patients. For this study, four health beliefs were drawn from the HBM and the revised HBM as described by Ronis (1992) . All beliefs except for perceived susceptibility were measured on a ve-point agreement scale. The internal consistency of multi-item scales was assessed and items were dropped from each scale if they failed to demonstrate adequate item-to-total correlations, i.e. r , 0.3 (Ferketich, 1991; Nunnally, 1978) . The resulting measures are presented below.
Perceived bene ts was a two-item scale re ecting what patients perceived they would derive from their treatment adherence behaviours (e.g. prolonging life and decreasing chance of getting worse). Perceived barriers was a four-item scale re ecting what patients perceived they would have to overcome to adhere to their antiretroviral therapy. Perceived barriers were explored as non-monetary (e.g. stress of treatment, side effects of drugs, interrupted social activities) and monetary (e.g. expenditures on drugs) (Nau, 1997; Ronis, 1992; Rosenstock 1966) .
Perceived severity was the perceived seriousness of the disease and was measured in comparison to other illnesses. Perceived susceptibility-inaction was the perceived chance of disease aggravatio n if not adherent to the treatment, and perceived susceptibility-action was the perceived chance of disease aggravation if adherent to the treatment. They were measured on a ve-point scale where 1 was 'very low' and 5 was 'very high'.
The complexity or burden of a medication regimen is a function of the number of doses per day, as well as special requirements regarding the use of the medication (such as take on an empty stomach). Currently, there is no consensus on the ideal way to assess medication regimen complexity. This study used the number of weekly doses as an indicator of regimen complexity. The score was calculated for each patient as the sum of weekly doses for all medications taken regularly. The doses for the medications prescribed for use 'as needed' (i.e. PRN) were not included unless the patient indicated that they took these medications frequently and regularly.
The measure of medication adherence operationally de ned adherence as the percentage of doses taken as prescribed during the last two days. This was measured as a continuous variable and calculated by the following formula ((prescribed doses 2 missed doses) i (prescribed doses)) (Samet et al., 1992) .
Data analysis
Statistical Package for Social Sciences (SPSS-7.5) was used for data analysis. Multivariate analysis of variance (MANOVA) was utilized to investigate the effects of disease severity on health beliefs. The independent variable was disease severity with three levels (A,B,C). The health beliefs served as dependent variables. A post hoc analysis was conducted since there were more than two levels in the multivariate main effect. Speci c comparisons among three levels of disease severity pointed out the source of the signi cant difference in each health belief.
The extent to which medication adherence varies across clinical category was assessed with a one-way ANOVA. Since regimen complexity may affect medication adherence and increase with disease severity, it was included as a covariate in this analysis. By doing so, the linear effect of regimen complexity upon the dependent variable (medication adherence) is removed separately from the effect of the factor categories (disease severity). Therefore, the main effect of disease severity was assessed after adherence scores were adjusted for differences associated with regimen complexity. This may increase the sensitivity of the test of main effect by reducing the interaction between medication adherence and regimen complexity.
A multiple regression model was used to investigate the in uence of regimen complexity, health beliefs and demographic factors on medication-taking behaviours. Previous studies showed that misunderstanding doctors' instructions was a common problem among patients and may have negative effects on medication adherence (Meichenbaum & Turk, 1987; Remien, 1998; Tseng, 1998) . Thus the item, 'It is dif cult to follow doctors' instructions on medications' was also included in the regression analysis. Stepwise method was used for regression analysis in order to understand the relative in uence of each independent variable on medication adherence. 
Results
Patient characteristics
Seventy-two patients completed the survey (Table 1) . Most patients were White (52.9%), male (73.1%) and with an age between 25 and 44 years old (78.0%). About 43% of respondents had college or graduate education and 70.6% of respondents earned less than 20,000 a year. Regarding the type of insurance coverage, Medicaid was the major payer for the patients surveyed (42.9%), followed by private insurance companies (22.1%) and the Ryan White Consortium (14.3%). Only three patients (3.9%) reported that they had to pay for HIV medications mainly by themselves. Clinical characteristics of the sample are presented in Table 2 . Most patients were in the rst (asymptomatic) and third (AIDS/ARC) stage (44.5% and 34.7%, respectively), compared to 20.8% of patients in stage two (HIV symptomatic). There are about equal numbers of patients in asymptomatic (A) stage and symptomatic (B and C) stage (44.5% and 55.5%, respectively). More than half of the patients (59.1%) reported taking three to ve medications, and 19.8% of the patients reported taking even more ( . 6) medications. Nearly all respondents (97.2%) indicated that they had been taking medications for HIV/AIDS for more than four months.
Health beliefs and adherence assessment
Most patients (83.2%) disagreed or strongly disagreed with the statement: 'Compared to other illness, HIV/AIDS is NOT very serious.' The mean 6 standard deviation (SD) was 4.28 6 1.11, on a ve-point scale ( Table 3 ). The majority of patients (73.4%) also rated their chances of getting worse 'high' or 'very high' if they did not take HIV medications as prescribed, with a mean and standard deviation of 4.05 and 0.98, respectively. Nearly two-thirds (63.7%) of the patients rated their chances of getting worse as 'low' or 'very low' if they take HIV medications as prescribed. The mean 6 SD of the perception score was 2.19 6 1.05. The perceived bene ts scale was comprised of two items, each of which was measured on a ve-point Likert scale (coef cient alpha 5 0.62). For both items, the means were higher than the midpoint, especially for the item, 'Taking medications as prescribed can prolong my life' (mean 6 SD 5 4.38 6 0.83).
Regarding the perceived barriers, the majority of patients agreed or strongly agreed that HIV medications caused annoying side effects (62.8%), dealing with the side effects was stressful (55.7%) and HIV medications were very expensive (60.0%). One item ('It is dif cult to follow doctors' instructions on medications') initially included in the non-monetary barriers scale was dropped because of its low item-to-total correlation (r 5 0.24). The resulting non-monetary barriers scale demonstrated a relatively high internal consistency (coef cient alpha 5 0.85).
The average number of missed doses during the past two days was 0.8. The medication adherence score ranged from 0 to 100%, with a mean of 93.1% during the past two days ( Table 3 ). The number of weekly doses ranged from 14 to 147, with a mean and SD of 54.94 and 24.26, respectively. Thus, patients took about eight doses a day on average.
Relationship of disease severity and health beliefs
The mean and standard deviations of health beliefs across three disease severity categories are presented in Table 4 . Using a 5 0.05, the multivariate tests did not show signi cant effects of disease severity on patients' health beliefs (Wilks' k 5 0.76, p 5 0.21). More speci cally, there was no statistically signi cant difference in patients' perceived severity of HIV/AIDS and perceptions of bene ts and barriers of the treatment across three disease stages. However, tests of between-subjects effects revealed that disease severity did in uence patients' perception of susceptibility-inaction (F 5 3.38, p 5 0.04). Further post hoc tests (LSD method) showed there were signi cant differences in perceived susceptibility-inaction between patients in stages A and C (p 5 0.01). Thus, patients who had greater experience with the disease were more likely to consider themselves at risk for complications if they did not take their medicine.
Relationship of disease severity and medication adherence
The mean level of medication adherence did increase as disease severity increased: the mean adherence scores were 90.29 6 12.82, 96.83 6 6.30, 98.84 6 3.20 for stages A, B and C, respectively ( Table 4 ). Results of further factorial ANOVA also revealed that the unique or main effect of disease severity on medication adherence was signi cant among three disease stages (F 5 3.85, p 5 0.03) (Table 5 ). However, the mean adherence score for stages B and C were very close. Thus, we combined those patients in stages B and C (symptomatic) and compared this symptomatic group to the asymptomatic patients in stage A. This resulted in a more dramatic difference in adherence scores (F 5 7.72, p 5 0.007) ( Table 5 ). Consequently, patients with some experience of HIV/AIDS complications were more adherent to their medications compared to patients who had never experienced complications.
Relationship of health beliefs and medication adherence
Results of the multiple regression analysis are presented in Table 6 . Two signi cant predictors of patients' medication adherence were detected. Perceived susceptibility-inaction was positively associated with their adherence (b 5 0.36, t 5 2.92, p , 0.01). The higher perceived chance of getting worse if not taking their medications as prescribed, the more likely that patients would be adherent. Medication adherence was also negatively related to the dif culty of following doctors' instructions on HIV medications (b 5 2 0.33, t 5 2 2.69, p , 0.01). Patients who perceived the doctors' instructions as more dif cult to follow were less adherent to their treatment. Other health beliefs did not signi cantly affect medication adherence. In addition, the regression analysis showed that regimen complexity alone was not a signi cant predictor of patients' medication adherence. Finally, no demographic factors such as age, gender, ethnicity, education and income were found to relate to medication adherence when controlling for health beliefs and regimen complexity. The nal regression model included two predictors: perceived susceptibility-inaction and dif culty in following doctors' instructions on HIV medications (F 5 8.00, p , 0.01).
Discussion
Relationship of disease severity and health beliefs
There was no relationship between the stage of HIV/AIDS and perceived comparative severity of the disease, or perceptions of bene ts of or barriers to the treatment. The majority of patients felt that HIV/AIDS was serious and the lack of substantial variability in responses made it dif cult to establish a relationship between perceived severity and actual severity. This result is comparable to the ndings of other compliance studies among HIV patients (Geletko, 1995; Morse, 1991; Muma, 1995) . In addition, most patients agreed their treatment was very bene cial regardless of their disease stage. This may be due to the fact that treatments for HIV/AIDS have improved remarkably in recent years. It may also be due to enhanced efforts within the study clinics to educate patients on the bene ts of antiretroviral medications. Thus it is reasonable that patients' perceived bene ts of the treatment are quite uniform and not in uenced by their actual disease severity.
Side effects from medications were the greatest perceived barrier. Despite developments in the effectiveness of HIV/AIDS medications, side effects of antiretrovirals are still relatively common (Carpenter et al., 1996) . Also, the combined antiretroviral therapy increases regimen complexity, which increases the burden of treatment. Patients without severe disease-related symptoms may perceive high treatment barriers because the side effects of their medications appear relatively intolerable compared to their symptom experience, whereas patients with advanced disease may perceive high treatment barriers because they actually experience a greater incidence of adverse effects. As the course of HIV disease progresses and treatment alternatives become limited, it is more likely that remaining treatment options will have overlapping adverse effect pro les (Carpenter et al., 1996) . But patients with AIDS or ARC may also perceive the side effects of medications and/or other inconveniences caused by the treatment more tolerable compared to the advancement of their disease. Regarding the monetary barrier, the perceived cost of medications was not signi cant, as more than 70% of patients in this study had some form of insurance coverage for medications.
Signi cantly, disease severity was associated with perceived susceptibility-inaction. HIV/ AIDS patients who have had complications perceive themselves to be at greater risk of getting worse when not adherent as compared to patients who have never experienced complications. It indicates that the disease experience plays an important role in the development of risk perception. The negative experience (undergoing complications) of patients reinforces their perception that the chance of disease getting worse will increase if not adherent. This is consistent with the ndings of previous studies (Conner & Norman, 1994; Geletko et al., 1995) . On the contrary, there was no signi cant difference in perceived susceptibility-action among HIV patients in different disease stages. This further veri ed the conclusion of Ronis (1992) , that susceptibility-inaction and susceptibility-action should be evaluated separately.
Relationship of disease severity and medication adherence
Patients' adherence to antiretroviral therapy increased as patients' disease severity increased when regimen complexity was controlled. The trend was more signi cant between asymptomatic patients (stage A) and symptomatic patients (stages B and C). Although one might expect less adherence in patients with more advanced HIV disease because of their increased medication needs and decreased level of physical functioning, this is often not the case. Patients who have experienced more disease symptoms are likely to have higher medication adherence. They may perceive a higher risk of complications or have more experience in coping with the barriers of the treatment (e.g. side effects) compared to patients in the early stages of the disease.
Relationship of health beliefs and regimen complexity with medication adherence
Based on the results of a multiple regression analysis, we conclude that patients are more likely to take their medications as prescribed if they have higher perceived susceptibilityinaction and/or less dif culty in understanding doctors' instructions. These ndings are consistent with other literature regarding health beliefs and treatment adherence (Remien, 1998; Ronis, 1992; Rosenstock, 1966; Tseng, 1998) . However, all other health beliefs were not signi cantly associated with adherence. Thus, they may not be the best predictors of medication adherence behaviours of HIV patients. It is understandable that the perceived severity of the disease (comparative), which the HBM holds as a predictor of adherence behaviour, is not signi cant in this study due to uniformly high perceptions of severity. This supports opinions of Rimer (1990) and Nau (1997) , that the concept of perceived severity in HBM may have low utility when applied to severe illnesses.
Regimen complexity was not a signi cant predictor of medication adherence when controlling for health beliefs. However, many studies have indicated that medication adherence is strongly associated with regimen complexity (Eldred et al., 1997; Eraker et al., 1984; Rudd, 1993; etc.) . The lack of association in this study may be due to the fact that more than 75% of the patients took at least ve doses a day and there was minimal variation in regimen complexity. It may also be due to limitations in the measure of regimen complexity. In this study, regimen complexity was calculated based on the number of daily doses. Complexity may actually be in uenced by other issues such as the timing of the doses. For example, having to take ve medications that are all taken at the same dosing interval (e.g. three times a day) may be easier than taking one medication twice daily, along with another medication doses three times a day and a third drug dosed four times a day.
Causal links
Although there is no way to draw a de nitive conclusion about the causality between disease severity, health beliefs (e.g. susceptibility-inaction) and medication adherence in this study, it is logical that patients' current medication adherence is in uenced by their past disease experiences. It is possible that the effect of disease severity on medication adherence is mediated by patients' perceived risk of getting worse given non-adherence (susceptibilityinaction). Greater experience in dealing with disease symptoms and medication use can lead to a higher perceived risk of complications. The perceived link between non-adherence and the development of complications may be reinforced through one's personal or vicarious experience of having developed complications when non-adherent. Counselling by health professionals on the dangers of non-adherence may also in uence this perception. The extant literature on the Health Belief Model suggests that a higher perceived susceptibility should translate into increased adherence behaviours. Conversely, patients who are in better health or who have had no symptoms may have poor medication adherence because they feel less immediately susceptible to the complications of the illness (i.e. low perceived susceptibilityinaction).
This study suggests directions for developing and promoting disease self-management in HIV patients. By understanding patients' medication-taking behaviours and addressing adherence-related issues from patients' perspectives, health care providers can play an important role in helping establish optimal adherence in HIV patients. This requires that health care providers invest time educating patients about their disease and its treatment. As shown in this study, dif culty in following physicians' instructions was a signi cant barrier to medication adherence. This suggests that patients' medication adherence can be improved by enhancing the relationship and communications between patients and health care providers. The ndings also revealed that asymptomatic patients perceive less risk in non-adherence and tend to take their medications less regularly. This suggests that the importance of treatment adherence and the risks of non-adherence should be emphasized to all patients, especially for those who have not yet experienced the complications of HIV infection. Effective counselling should inform patients that non-adherence may cause disease aggravatio n and the failure of drug therapy which will limit future antiretroviral options because of cross-resistance. Finally, since patients often learn best from personal or vicarious experience, it may be good to encourage the participation of newly diagnosed HIV patients in support groups with more experienced patients. If the experienced patients can share their insight on the consequences of non-adherence, the newer patients may gain a better understanding of the risks associated with non-adherence. This ultimately could lead to better adherence among newly diagnosed patients.
